Table 2. Summary of other treatments before or after regorafenib.
| Treatment | Sorafenib group (%) | Lenvatinib group (%) | Total (%) | P |
|---|---|---|---|---|
| Surgery a | ||||
| N | 9 (40.9) | 14 (50.0) | 23 (46.0) | 0.522 |
| Y | 13 (59.1) | 14 (50.0) | 27 (54.0) | |
| Ablation a | ||||
| N | 17 (77.3) | 23 (82.1) | 40 (80.0) | 0.669 |
| Y | 5 (22.7) | 5 (17.9) | 10 (20.0) | |
| TACE a | ||||
| N | 3 (13.6) | 5 (17.9) | 8 (16.0) | 0.686 |
| Y | 19 (86.4) | 23 (82.1) | 42 (84.0) | |
| Radiotherapy a | ||||
| N | 21 (95.5) | 23 (82.1) | 44 (88.0) | 0.131 |
| Y | 1 (4.5) | 5 (17.9) | 6 (12.0) | |
| Immunotherapy a | ||||
| N | 8 (13.6) | 8 (14.3) | 16 (32.0) | 0.558 |
| Y | 14 (63.6) | 20 (71.4) | 34 (68.0) | |
| Ablation b | ||||
| N | 20 (90.9) | 25 (89.3) | 45 (90.0) | 0.849 |
| Y | 2 (9.1) | 3 (10.7) | 5 (10.0) | |
| TACE b | ||||
| N | 11 (50.0) | 15 (53.6) | 26 (52.0) | 0.802 |
| Y | 11 (50.0) | 13 (46.4) | 24 (48.0) | |
| Radiotherapy b | ||||
| N | 21 (95.5) | 26 (92.9) | 47 (94.0) | 0.698 |
| Y | 1 (4.5) | 2 (7.1) | 3 (6.0) | |
| Immunotherapy b | ||||
| N | 2 (9.1) | 4 (14.3) | 6 (12.0) | 0.683 |
| Y | 20 (90.9) | 24 (85.7) | 44 (88.0) |
a, treatment before accepting regorafenib; b, treatment after accepting regorafenib; TACE, transcatheter arterial chemoembolization; N, no; Y, yes.